Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 19/20 | 0.48 |
| ▸ | KLRK1 | P26718 | 1/20 | 0.36 |
| ▸ | MICA | Q29983 | 1/20 | 0.36 |
| ▸ | RAET1L | Q5VY80 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1349967 | 0.85 | SLC6A9 (0.48) | SLC6A9 | |
| SCHEMBL1349381 | 0.85 | SLC6A9 (0.51) | SLC6A9CYP2D6CYP2C19SLC6A5 | |
| SCHEMBL1348599 | 0.84 | SLC6A9 (0.50) | SLC6A9 | |
| SCHEMBL1347772 | 0.84 | SLC6A9 (0.53) | SLC6A9KLRK1MICARAET1LCYP2D6 | |
| SCHEMBL1349456 | 0.83 | SLC6A9 (0.52) | SLC6A9KLRK1MICARAET1LCYP2D6 | |
| SCHEMBL1350134 | 0.83 | SLC6A9 (0.49) | SLC6A9CYP2D6CYP2C19SLC6A5 | |
| SCHEMBL1350169 | 0.81 | SLC6A9 (0.54) | SLC6A9KLRK1MICARAET1LCYP2D6 | |
| SCHEMBL1350715 | 0.80 | SLC6A9 (0.49) | SLC6A9KLRK1MICARAET1L | |
| SCHEMBL1348675 | 0.79 | SLC6A9 (0.51) | SLC6A9KLRK1MICARAET1LCYP2D6 | |
| SCHEMBL3264199 | 0.78 | SLC6A9 (0.47) | SLC6A9CYP2D6CYP2C19SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063098-B2 | GlyT1 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063098-B2 | GlyT1 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063098-B2 | GlyT1 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20100048531-A1 | GlyT1 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20100048531-A1 | GlyT1 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20100048531-A1 | GlyT1 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048531-A1 | GlyT1 RECEPTOR ANTAGONISTS | GLRA1, GLRA2, GRIA1 | SLC6A9 20/4885KLRK1 1606/4885MICA 2450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.